Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Change in Receivables: 2011-2024

Historic Change in Receivables for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to -$1.7 million.

  • Ptc Therapeutics' Change in Receivables fell 16.13% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year decrease of 127.37%. This contributed to the annual value of -$1.7 million for FY2024, which is 212.54% down from last year.
  • As of FY2024, Ptc Therapeutics' Change in Receivables stood at -$1.7 million, which was down 212.54% from $1.5 million recorded in FY2023.
  • Ptc Therapeutics' 5-year Change in Receivables high stood at $48.5 million for FY2022, and its period low was -$1.7 million during FY2024.
  • Over the past 3 years, Ptc Therapeutics' median Change in Receivables value was $1.5 million (recorded in 2023), while the average stood at $16.1 million.
  • In the last 5 years, Ptc Therapeutics' Change in Receivables spiked by 329.18% in 2021 and then plummeted by 212.54% in 2024.
  • Over the past 5 years, Ptc Therapeutics' Change in Receivables (Yearly) stood at $10.5 million in 2020, then skyrocketed by 329.18% to $45.0 million in 2021, then rose by 7.73% to $48.5 million in 2022, then plummeted by 96.82% to $1.5 million in 2023, then crashed by 212.54% to -$1.7 million in 2024.